Alyssa Milliron, MD
Internal Medicine · Chico, CANPI 1033640099
Payments from drug & device makers
Across 189 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$542
- Novo Nordisk$504
- Daiichi Sankyo Inc.$381
- Merck$262
- Indivior Inc.$256
- Viiv Healthcare Company$222
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $542 |
| Novo Nordisk | 19 | $504 |
| Daiichi Sankyo Inc. | 31 | $381 |
| Merck | 11 | $262 |
| Indivior Inc. | 9 | $256 |
| Viiv Healthcare Company | 9 | $222 |
| Pfizer | 9 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $195 |
| Lilly USA, LLC | 7 | $139 |
| AstraZeneca | 6 | $103 |
| Bayer | 5 | $96 |
| Amgen | 4 | $91 |
| Exact Sciences | 4 | $72 |
| Alk-abello, Inc | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| GSK | 3 | $51 |
| Hologic Sales And Service, LLC | 2 | $48 |
| Johnson & Johnson | 2 | $44 |
| Dexcom, Inc. | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Theratechnologies Inc. | 1 | $22 |
| Qiagen, LLC | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $14 |
| Incyte Corporation | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$116
How this compares
$3,573 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $111,427 |
| JardianceEmpagliflozin | 64 | $69,436 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $34,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $29,042 |
| BelbucaBuprenorphine Hcl | 35 | $22,605 |
| TrulicityDulaglutide | 14 | $19,156 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $18,691 |
| EntrestoSacubitril/Valsartan | 11 | $14,190 |
| MounjaroTirzepatide | 13 | $13,250 |
| VascepaIcosapent Ethyl | 37 | $12,621 |
| EliquisApixaban | 11 | $11,066 |
| JanuviaSitagliptin Phosphate | 16 | $9,234 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $7,894 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,703 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $504 | $111,42774 claims |
| Boehringer IngelheimJardiance | $17 | $69,43664 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $51 | $50,46361 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $139 | $33,49856 claims |
| PfizerEliquis | $200 | $11,06611 claims |
| MerckJanuvia | $262 | $9,23416 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $195 | $6,49312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Chico
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.